Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAUL K WINNER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology with Special Qualifications in Child Neurology

NPI
1831201243
CMS profile
1268856
Location
WEST PALM BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$196,438.99

215 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 215 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAUL K WINNER

NPI 1831201243 · CMS profile ID 1268856

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology with Special Qualifications in Child Neurology

WEST PALM BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 215 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1831201243?year=2020&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAUL K WINNER, NPI 1831201243, CMS profile ID 1268856. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 215 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1831201243?year=2020&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). PAUL K WINNER, NPI 1831201243, CMS profile ID 1268856. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 215 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1831201243?year=2020&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
PAUL K WINNER, NPI 1831201243, CMS profile ID 1268856, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 215 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1831201243?year=2020&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

215 matching records · $196,438.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 215 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 215.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lundbeck LLC $1,250.0005/28/2020 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747580817 CMS
US WorldMeds, LLC $23.6205/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749604499 CMS
Lundbeck LLC $19.0605/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747580815 CMS
Upsher-Smith Laboratories LLC $12.7205/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733051045 CMS
Supernus Pharmaceuticals, Inc. $24.9205/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748371471 CMS
Teva Pharmaceuticals USA, Inc. $11.9405/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749494285 CMS
Teva Pharmaceuticals USA, Inc. $2,880.0005/15/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749526535 CMS
Allergan, Inc. $400.0005/11/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723509343 CMS
Lundbeck LLC $1,250.0005/05/2020 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747580811 CMS
Lundbeck LLC $1,250.0005/05/2020 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747580813 CMS
Teva Pharmaceuticals USA, Inc. $9,070.0004/29/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749526531 CMS
Teva Pharmaceuticals USA, Inc. $11.7204/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749458107 CMS
Lundbeck LLC $2,000.0004/18/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747580809 CMS
Teva Pharmaceuticals USA, Inc. $1,600.0004/03/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749526525 CMS
Lundbeck LLC $1,000.0004/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747580807 CMS
Lilly USA, LLC $950.0003/24/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728581215 CMS
Lilly USA, LLC $1,068.7503/24/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728588113 CMS
Lilly USA, LLC $2,612.5003/12/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728591641 CMS
Teva Pharmaceuticals USA, Inc. $17.4203/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749497225 CMS
Allergan, Inc. $2,400.0003/11/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723509339 CMS
Allergan, Inc. $17.7603/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723509341 CMS
Lundbeck LLC $19.5803/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747580805 CMS
Lundbeck LLC $746.7903/06/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747580799 CMS
Lundbeck LLC $398.0003/06/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747580801 CMS
Lundbeck LLC $2,500.0003/06/2020 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747580803 CMS
Teva Pharmaceuticals USA, Inc. $5,760.0002/28/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749526505 CMS
Upsher-Smith Laboratories LLC $18.0802/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733039895 CMS
Teva Pharmaceuticals USA, Inc. $466.0002/21/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749517501 CMS
Allergan, Inc. $11.1702/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723509333 CMS
Allergan, Inc. $88.5302/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723509335 CMS
Allergan, Inc. $3,000.0002/20/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723509337 CMS
Teva Pharmaceuticals USA, Inc. $16.1702/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749454319 CMS
Teva Pharmaceuticals USA, Inc. $5,040.0002/07/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749526507 CMS
ACADIA Pharmaceuticals Inc $13.9102/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748583583 CMS
Lilly USA, LLC $431.3902/06/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728578075 CMS
Allergan, Inc. $2.2302/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723509329 CMS
Allergan, Inc. $2.0202/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723509331 CMS
Assertio Therapeutics, Inc. $22.5602/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748831925 CMS
Teva Pharmaceuticals USA, Inc. $637.2002/04/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749526509 CMS
Supernus Pharmaceuticals, Inc. $21.3602/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748371467 CMS
Teva Pharmaceuticals USA, Inc. $121.8702/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749526547 CMS
Allergan, Inc. $2,400.0001/31/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723509325 CMS
Allergan, Inc. $28.1001/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723509327 CMS
Teva Pharmaceuticals USA, Inc. $12.2701/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749496405 CMS
Allergan, Inc. $20.3501/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723509323 CMS
Allergan, Inc. $22.4001/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723509319 CMS
Allergan, Inc. $2,400.0001/29/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723509321 CMS
Allergan, Inc. $93.2801/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723509305 CMS
Allergan, Inc. $3,500.0001/25/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723509307 CMS
Allergan, Inc. $150.9201/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723509309 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $163,070.83 232
PY2020 $196,438.99 215
PY2021 $137,249.50 215
PY2022 $65,318.38 157
PY2023 $27,360.71 153
PY2024 $18,569.35 127
PY2025 $16,215.16 112

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,180,569.12 226
PY2024 Recipient $49,836.22 9
PY2024 Principal investigator $3,062,085.96 126
PY2023 Recipient $19,779.76 7
PY2023 Principal investigator $3,600,760.06 86
PY2022 Recipient $805.00 2
PY2022 Principal investigator $2,598,150.72 58
PY2021 Recipient $995.29 2
PY2021 Principal investigator $1,254,355.20 100
PY2020 Recipient $510.84 3
PY2020 Principal investigator $1,374,402.46 113
PY2019 Recipient $3,596.00 1
PY2019 Principal investigator $701,516.02 72

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

226 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $300.00 12/31/2025 Non-covered Recipient Entity
PREMIERE RESEARCH INSTITUTE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects with Early Alzheimer s Disease No dispute reported 06/30/2026 1202534305
Principal investigator 1 Janssen Research & Development, LLC $20,427.00 12/29/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175399520
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,356.00 12/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242369747
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,356.00 12/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242369749
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $174.00 12/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242369751
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,767.00 12/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242369753
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,203.00 12/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242369755
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,741.00 12/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242369757
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $50.00 12/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242369759
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $92.00 12/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242369761
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,203.00 12/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242369763
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,741.00 12/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242369765
Principal investigator 1 Janssen Research & Development, LLC $16,570.00 12/22/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175399392
Principal investigator 1 H. Lundbeck A S $1,300.00 12/19/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251778651
Principal investigator 1 Janssen Research & Development, LLC $11,706.00 12/19/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399378
Principal investigator 1 Janssen Research & Development, LLC $2,300.00 12/18/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399403
Principal investigator 1 Eisai Inc. $19,296.00 12/17/2025 Non-covered Recipient Entity
Premiere Research Institute at Palm Beach Neurology
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244560446
Principal investigator 1 Janssen Research & Development, LLC $1,629.00 12/12/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399372
Principal investigator 1 Janssen Research & Development, LLC $736.00 12/12/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175399513
Principal investigator 1 H. Lundbeck A S $2,734.00 12/01/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251777871
Principal investigator 1 H. Lundbeck A S $1,958.00 12/01/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251777875
Principal investigator 1 H. Lundbeck A S $557.00 12/01/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251777878
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,342.00 11/25/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242367847
Principal investigator 1 Eisai Inc. $19,606.50 11/20/2025 Non-covered Recipient Entity
Premiere Research Institute at Palm Beach Neurology
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244560448
Principal investigator 1 GENZYME CORPORATION $23,604.00 11/17/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097781
Principal investigator 1 GENZYME CORPORATION $450.00 11/17/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097787
Principal investigator 1 GENZYME CORPORATION $15,440.00 11/17/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097792
Principal investigator 1 Janssen Research & Development, LLC $1,629.00 11/14/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175399489
Principal investigator 1 Merz Pharmaceuticals, LLC $2,000.00 11/14/2025 Non-covered Recipient Entity
PREMIERE RESEARCH INSTITUTE
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647462
Principal investigator 1 Merz Pharmaceuticals, LLC $13,850.00 11/14/2025 Non-covered Recipient Entity
PREMIERE RESEARCH INSTITUTE
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647468
Principal investigator 1 Janssen Research & Development, LLC $12,075.00 11/13/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175399482
Principal investigator 1 Merz Pharmaceuticals, LLC $2,000.00 11/07/2025 Non-covered Recipient Entity
PREMIERE RESEARCH INSTITUTE
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647464
Principal investigator 1 Merz Pharmaceuticals, LLC $13,850.00 11/07/2025 Non-covered Recipient Entity
PREMIERE RESEARCH INSTITUTE
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647466
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $118.00 11/05/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242365727
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $118.00 11/05/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242365729
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $118.00 11/05/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242365731
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $118.00 11/05/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242365733
Principal investigator 1 Janssen Research & Development, LLC $3,484.00 11/03/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399352
Principal investigator 1 Janssen Research & Development, LLC $6,032.00 11/03/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399475
Principal investigator 1 Novo Nordisk AS $431.55 10/30/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
NN6535-4725 No dispute reported 06/30/2026 1213729723
Principal investigator 1 Novartis Pharmaceuticals Corporation $69,954.59 10/27/2025 Non-covered Recipient Entity
PREMIERE RESEARCH INSTITUTE
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190302423
Principal investigator 1 Eisai Inc. $13,696.20 10/24/2025 Non-covered Recipient Entity
Premiere Research Institute at Palm Beach Neurology
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244560444
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,342.00 10/22/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242365017
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,334.00 10/22/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242365019
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,334.00 10/22/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242365021
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $824.00 10/22/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242365023
Principal investigator 1 H. Lundbeck A S $2,734.00 10/15/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775665
Principal investigator 1 H. Lundbeck A S $557.00 10/15/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775668
Principal investigator 1 H. Lundbeck A S $2,816.00 10/15/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775673
Principal investigator 1 H. Lundbeck A S $2,648.00 10/15/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775677
Principal investigator 1 Eli Lilly and Company $25.20 10/07/2025 Non-covered Recipient Entity
NEUROLOGY RESEARCH INSTITUTE PALM BEACH LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187885908
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,200.00 10/03/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244046884
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 10/03/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244046886
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,200.00 10/03/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244046952
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $824.00 10/02/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242361709
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,842.00 10/02/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242361711
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $824.00 10/02/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242361713
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,563.00 10/02/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242361715
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $824.00 10/02/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242361717
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,842.00 10/02/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242361719
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $824.00 10/02/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242361721
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,563.00 10/02/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242361723
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $824.00 10/02/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242361725
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,064.00 10/02/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242361727
Principal investigator 1 GENZYME CORPORATION $7,440.00 09/29/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097701
Principal investigator 1 GENZYME CORPORATION $4,800.00 09/22/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097689
Principal investigator 1 Eisai Inc. $209.91 09/17/2025 Non-covered Recipient Entity
Premiere Research Institute at Palm Beach Neurology
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244560436
Principal investigator 1 Eisai Inc. $9,370.80 09/17/2025 Non-covered Recipient Entity
Premiere Research Institute at Palm Beach Neurology
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244560442
Principal investigator 1 H. Lundbeck A S $2,816.00 09/10/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774559
Principal investigator 1 H. Lundbeck A S $557.00 09/10/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774563
Principal investigator 1 Janssen Research & Development, LLC $500.00 09/05/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399424
Principal investigator 1 Janssen Research & Development, LLC $7,441.00 09/04/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399430
Principal investigator 1 Janssen Research & Development, LLC $3,538.00 09/04/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399537
Principal investigator 1 GENZYME CORPORATION $175.00 09/03/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097656
Principal investigator 1 GENZYME CORPORATION $1,500.00 09/03/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226097674
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,064.00 08/25/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242358132
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $824.00 08/25/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242358134
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,563.00 08/25/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242358136
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,767.00 08/25/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242358138
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $824.00 08/25/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242358140
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,563.00 08/25/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242358142
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $824.00 08/25/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242358144
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,060.00 08/25/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242358146
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $50.00 08/25/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242358148
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $92.00 08/25/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242358150
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $236.00 08/25/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242358178
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $236.00 08/25/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242358180
Principal investigator 1 GENZYME CORPORATION $750.00 08/18/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097643
Principal investigator 1 GENZYME CORPORATION $1,500.00 08/18/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097650
Principal investigator 1 Janssen Research & Development, LLC $368.00 08/14/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175399455
Principal investigator 1 Eisai Inc. $17,908.20 08/13/2025 Non-covered Recipient Entity
Premiere Research Institute at Palm Beach Neurology
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244560432
Principal investigator 1 GENZYME CORPORATION $29,040.00 08/11/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097624
Principal investigator 1 Janssen Research & Development, LLC $9,145.00 08/11/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175399471
Principal investigator 1 H. Lundbeck A S $2,734.00 08/07/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251773398
Principal investigator 1 H. Lundbeck A S $557.00 08/07/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251773403
Principal investigator 1 H. Lundbeck A S $2,648.00 08/07/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251773407
Principal investigator 1 GENZYME CORPORATION $100.00 08/04/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097585
Principal investigator 1 GENZYME CORPORATION $8,876.00 08/04/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097591
Principal investigator 1 GENZYME CORPORATION $5,646.00 08/04/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226097618
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $354.00 08/04/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242355744
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $354.00 08/04/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242355746
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,000.00 08/01/2025 Non-covered Recipient Entity
Premiere Research Institute
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1235994537
Principal investigator 1 GENZYME CORPORATION $4,800.00 07/28/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097602
Principal investigator 1 GENZYME CORPORATION $150.00 07/28/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097607
Principal investigator 1 GENZYME CORPORATION $100.00 07/28/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097612
Principal investigator 1 Eisai Inc. $17,260.20 07/23/2025 Non-covered Recipient Entity
Premiere Research Institute at Palm Beach Neurology
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244560434
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,356.00 07/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242355406
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,356.00 07/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242355408
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,356.00 07/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242355410
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,356.00 07/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242355412
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,356.00 07/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242355414
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,356.00 07/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242355416
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $824.00 07/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242355418
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,060.00 07/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242355420
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,203.00 07/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242355422
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,741.00 07/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242355424
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,203.00 07/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242355426
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,741.00 07/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242355428
Principal investigator 1 Janssen Research & Development, LLC $400.00 07/21/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399386
Principal investigator 1 H. Lundbeck A S $1,482.00 07/18/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251772687
Principal investigator 1 H. Lundbeck A S $1,550.00 07/18/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251772690
Principal investigator 1 H. Lundbeck A S $10,500.00 07/18/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251772694
Principal investigator 1 H. Lundbeck A S $500.00 07/18/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251772698
Principal investigator 1 H. Lundbeck A S $2,052.00 07/18/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251772703
Principal investigator 1 H. Lundbeck A S $900.00 07/18/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251772707
Principal investigator 1 Janssen Research & Development, LLC $15,205.00 07/11/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175399460
Principal investigator 1 H. Lundbeck A S $4,068.00 07/10/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251772046
Principal investigator 1 Eisai Inc. $24,262.20 07/09/2025 Non-covered Recipient Entity
Premiere Research Institute at Palm Beach Neurology
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244560438
Principal investigator 1 Eisai Inc. $222.88 07/09/2025 Non-covered Recipient Entity
Premiere Research Institute at Palm Beach Neurology
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244560440
Principal investigator 1 H. Lundbeck A S $2,734.00 07/09/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251771963
Principal investigator 1 H. Lundbeck A S $557.00 07/09/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251771967
Principal investigator 1 H. Lundbeck A S $2,648.00 07/09/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251771971
Principal investigator 1 GENZYME CORPORATION $9,440.00 07/02/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097572
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $685.03 06/24/2025 Non-covered Recipient Entity
Premiere Research Institute At Palm Beach Neurology
Phase III Safety and Efficacy of KarXT in Psychosis Associated with AD (ADEPT 4): 2 of 2 Acute Studies No dispute reported 06/30/2026 1235994533
Principal investigator 1 Novo Nordisk AS $4,350.00 06/23/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
NN6535-4725 No dispute reported 06/30/2026 1213756292
Principal investigator 1 Janssen Research & Development, LLC $2,208.00 06/12/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175399501
Principal investigator 1 Janssen Research & Development, LLC $7,000.00 06/09/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399532
Principal investigator 1 H. Lundbeck A S $2,734.00 06/06/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251771070
Principal investigator 1 H. Lundbeck A S $2,648.00 06/06/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251771074
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,000.00 06/03/2025 Non-covered Recipient Entity
PREMIER RESEARCH INSTITUTE AT PALM BEACH NEUROLOGY
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190300241
Principal investigator 1 GENZYME CORPORATION $38,880.00 05/19/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097490
Principal investigator 1 Eli Lilly and Company $21.49 05/16/2025 Non-covered Recipient Entity
PREMIER RESEARCH INSTITUTE
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187887996
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $354.00 05/16/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242347480
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,104.00 05/16/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242347482
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $303.00 05/16/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242347484
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $324.00 05/16/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242347486
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $354.00 05/16/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242347488
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $291.00 05/16/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242347490
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,000.00 05/16/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242347492
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $850.00 05/16/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242347494
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $10,000.00 05/16/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242347496
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,616.00 05/16/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242347498
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,100.00 05/16/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242347500
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,037.00 05/16/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
ITI-1284-101 No dispute reported 06/30/2026 1242347502
Principal investigator 1 Amgen Inc. $63,153.30 05/15/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis No dispute reported 06/30/2026 1246646250
Principal investigator 1 H. Lundbeck A S $1,855.55 05/15/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251770250
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,500.00 05/13/2025 Non-covered Recipient Entity
PREMIER RESEARCH INSTITUTE AT PALM BEACH NEUROLOGY
A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy No dispute reported 06/30/2026 1190300237
Principal investigator 1 Janssen Research & Development, LLC $200.00 05/08/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399362
Principal investigator 1 Janssen Research & Development, LLC $300.00 05/08/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399367
Principal investigator 1 Janssen Research & Development, LLC $500.00 05/08/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399383
Principal investigator 1 Janssen Research & Development, LLC $300.00 05/08/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399451
Principal investigator 1 Janssen Research & Development, LLC $300.00 05/08/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399495
Principal investigator 1 Janssen Research & Development, LLC $400.00 05/08/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399526
Principal investigator 1 GENZYME CORPORATION $5,000.00 05/05/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097475
Principal investigator 1 Janssen Research & Development, LLC $2,168.00 05/05/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175399508
Principal investigator 1 Janssen Research & Development, LLC $871.00 05/02/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399411
Principal investigator 1 Janssen Research & Development, LLC $1,502.00 05/02/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399417
Principal investigator 1 Janssen Research & Development, LLC $871.00 05/02/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399465
Principal investigator 1 GENZYME CORPORATION $300.00 04/28/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097463
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $968.50 04/28/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244046882
Principal investigator 1 GENZYME CORPORATION $8,464.00 04/21/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097469
Principal investigator 1 Eli Lilly and Company $1.68 04/16/2025 Non-covered Recipient Entity
PREMIER RESEARCH INSTITUTE
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187887564
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 04/08/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244046876
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,200.00 04/08/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244046878
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $173.71 04/08/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244046880
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,200.00 04/08/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244046950
Principal investigator 1 Janssen Research & Development, LLC $1,121.00 04/07/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399342
Principal investigator 1 Janssen Research & Development, LLC $3,149.00 04/07/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399485
Principal investigator 1 Janssen Research & Development, LLC $3,823.00 04/07/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399542
Principal investigator 1 PFIZER INC. $4,500.00 04/04/2025 Non-covered Recipient Entity
Palm Beach Neurology
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228777557
Principal investigator 1 Novartis Pharmaceuticals Corporation $37,054.74 03/31/2025 Non-covered Recipient Entity
PREMIERE RESEARCH INSTITUTE
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190310470
Principal investigator 1 Eli Lilly and Company $4,535.10 03/25/2025 Non-covered Recipient Entity
ATLANTA CENTER FOR MEDICAL RESEARCH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187875987
Principal investigator 1 H. Lundbeck A S $2,652.85 03/25/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251769056
Principal investigator 1 GENZYME CORPORATION $5,125.00 03/24/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097358
Principal investigator 1 Janssen Research & Development, LLC $71,544.00 03/24/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175399348
Principal investigator 1 Eisai Inc. $32,067.90 03/21/2025 Non-covered Recipient Entity
Premiere Research Institute at Palm Beach Neurology
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244560428
Principal investigator 1 GENZYME CORPORATION $17,828.00 03/17/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097191
Principal investigator 1 ABBVIE INC. $2,175.00 03/13/2025 Non-covered Recipient Entity
PREMIER RESEARCH INSTITUTE
M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202463005
Principal investigator 1 Eli Lilly and Company $12,839.92 03/10/2025 Non-covered Recipient Entity
PREMIER RESEARCH INSTITUTE
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187889172
Principal investigator 1 Janssen Research & Development, LLC $4,621.00 03/07/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399358
Principal investigator 1 Janssen Research & Development, LLC $1,029.00 03/07/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399398
Principal investigator 1 Janssen Research & Development, LLC $1,502.00 03/07/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399434
Principal investigator 1 GENZYME CORPORATION $19,200.00 03/04/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097395
Principal investigator 1 H. Lundbeck A S $3,578.50 03/04/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251768073
Principal investigator 1 Eli Lilly and Company $1,845.50 02/25/2025 Non-covered Recipient Entity
PREMIER RESEARCH INSTITUTE
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187890034
Principal investigator 1 GENZYME CORPORATION $16,264.00 02/18/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097184
Principal investigator 1 GENZYME CORPORATION $75.00 02/18/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097376
Principal investigator 1 H. Lundbeck A S $1,855.55 02/18/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251767437
Principal investigator 1 Eli Lilly and Company $24.15 02/07/2025 Non-covered Recipient Entity
PREMIER RESEARCH INSTITUTE
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187888150
Principal investigator 1 Janssen Research & Development, LLC $7,583.00 02/06/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175399445
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $94,425.92 02/05/2025 Non-covered Recipient Entity
Premiere Research Institute
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) No dispute reported 06/30/2026 1235994535
Principal investigator 1 H. Lundbeck A S $4,068.00 02/05/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251767018
Principal investigator 1 Eli Lilly and Company $4,395.20 01/31/2025 Non-covered Recipient Entity
PREMIER RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187888700
Principal investigator 1 Novartis Pharmaceuticals Corporation $45,571.02 01/31/2025 Non-covered Recipient Entity
PREMIERE RESEARCH INSTITUTE
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190307091
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,207,680.85 01/29/2025 Non-covered Recipient Entity
Premiere Research Institute At Palm Beach Neurology
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235994531
Principal investigator 1 H. Lundbeck A S $4,529.65 01/29/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766759
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,335.88 01/28/2025 Non-covered Recipient Entity
PREMIER RESEARCH INSTITUTE AT PALM BEACH NEUROLOGY
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190300239
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $12,491.58 01/27/2025 Non-covered Recipient Entity
Premiere Research Institute At Palm Beach Neurology
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235994529
Principal investigator 1 Eli Lilly and Company $13,635.26 01/27/2025 Non-covered Recipient Entity
ATLANTA CENTER FOR MEDICAL RESEARCH
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187875015
Principal investigator 1 Janssen Research & Development, LLC $23,848.00 01/24/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175399439
Principal investigator 1 Eisai Inc. $18,351.90 01/23/2025 Non-covered Recipient Entity
Premiere Research Institute at Palm Beach Neurology
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244560426
Principal investigator 1 Eisai Inc. $22,306.50 01/23/2025 Non-covered Recipient Entity
Premiere Research Institute at Palm Beach Neurology
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244560430
Principal investigator 1 Eli Lilly and Company $361,755.55 01/22/2025 Non-covered Recipient Entity
PREMIER RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187887958
Principal investigator 1 Eli Lilly and Company $1,149,126.19 01/21/2025 Non-covered Recipient Entity
PREMIER RESEARCH INSTITUTE
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187887562
Principal investigator 1 GENZYME CORPORATION $37,704.00 01/13/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226097363
Principal investigator 1 GENZYME CORPORATION $17,616.00 01/13/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226097370
Principal investigator 1 GENZYME CORPORATION $15,410.00 01/13/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226097381
Principal investigator 1 GENZYME CORPORATION $18,616.00 01/13/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226097386
Principal investigator 1 GENZYME CORPORATION $1,882.00 01/13/2025 Non-covered Recipient Entity
Palm Beach Neurology Premiere Research Institute
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226097390
Principal investigator 1 Amgen Inc. $160.00 01/12/2025 Non-covered Recipient Entity
PREMIERE RESEARCH INSTITUTE
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis No dispute reported 06/30/2026 1246646754
Principal investigator 1 PFIZER INC. $4,500.00 01/09/2025 Non-covered Recipient Entity
Palm Beach Neurology
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228765596
Principal investigator 1 H. Lundbeck A S $2,652.85 01/07/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766265
Principal investigator 1 H. Lundbeck A S $9,666.20 01/07/2025 Non-covered Recipient Entity
PALM BEACH NEUROLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766269
Principal investigator 1 Eli Lilly and Company $551,361.69 01/06/2025 Non-covered Recipient Entity
PREMIER RESEARCH INSTITUTE
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187887566
Principal investigator 1 Eli Lilly and Company $230,180.83 01/06/2025 Non-covered Recipient Entity
PREMIER RESEARCH INSTITUTE
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187889174
Principal investigator 1 Novartis Pharmaceuticals Corporation $214,925.35 01/01/2025 Non-covered Recipient Entity
PREMIERE RESEARCH INSTITUTE
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190302839